TPWA
CORT icon

Twin Peaks Wealth Advisors’s Corcept Therapeutics CORT Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.33K Buy
+157
New +$5.87K ﹤0.01% 1285
2025
Q3 		– Sell
-299
Closed -$22K – 566
2025
Q2 		$22K Buy
+299
New +$21.7K 0.01% 569

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Twin Peaks Wealth Advisors's CORT Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Corcept Therapeutics (CORT) in Q1 2026: 157 shares worth $6.33K. The stake represents ﹤0.01% of the portfolio and ranks #1285 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in CORT as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in CORT in Q2 2025 and has held it in 2 quarters since. The position peaked at $22K in Q2 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Twin Peaks Wealth Advisors held 157 shares of Corcept Therapeutics worth $6.33K as of Q1 2026.
  • Corcept Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Corcept Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #1285 holding.
  • Twin Peaks Wealth Advisors first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Twin Peaks Wealth Advisors's Corcept Therapeutics position peaked at $22K in Q2 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.